NRX Pharmaceuticals, Inc. Warrant (NRXPW)

• Market cap: $1.31M
• 1 day: -8.07%
• 5 days: -3.43%
• 1 month: -18.18%
• 3 months: 45.40%
• 6 months: -68.97%
• Year to date: -52.63%
• 1 year: 15.38%
• 5 years: -76.32%
• 10 years: -74.43%
• Sector: Healthcare
• Industry: Biotechnology

About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.14% less ownership

Funds ownership: 0.65% [Q4 2024] → 0.51% (-0.14%) [Q1 2025]

20% less funds holding

Funds holding: 5 [Q4 2024] → 4 (-1) [Q1 2025]

39% less capital invested

Capital invested by funds: $10.2K [Q4 2024] → $6.16K (-$4K) [Q1 2025]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1